EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
Authors
Keywords
-
Journal
Orphanet Journal of Rare Diseases
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-03
DOI
10.1186/s13023-019-1262-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
- (2019) Velina S. Atanasova et al. CLINICAL CANCER RESEARCH
- Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years’ experience of a reference centre in Spain
- (2019) B. Castelo et al. Clinical & Translational Oncology
- Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand
- (2018) M Kim et al. ACTA DERMATO-VENEREOLOGICA
- Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
- (2018) Robert L. Ferris et al. CANCER TREATMENT REVIEWS
- Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas
- (2018) Melanie C. Föll et al. MATRIX BIOLOGY
- Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases
- (2016) H. Montaudié et al. Orphanet Journal of Rare Diseases
- Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines
- (2015) J.E. Mellerio et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas
- (2015) M. Reigneau et al. BRITISH JOURNAL OF DERMATOLOGY
- Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma
- (2013) M. Kim et al. BRITISH JOURNAL OF DERMATOLOGY
- Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- (2011) Eve Maubec et al. JOURNAL OF CLINICAL ONCOLOGY
- Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma
- (2010) A.K. Kivisaari et al. BRITISH JOURNAL OF DERMATOLOGY
- Dystrophic Epidermolysis Bullosa: Pathogenesis and Clinical Features
- (2009) Leena Bruckner-Tuderman DERMATOLOGIC CLINICS
- Cetuximab Therapy of Metastasizing Cutaneous Squamous Cell Carcinoma in a Patient with Severe Recessive Dystrophic Epidermolysis Bullosa
- (2009) Andreas W. Arnold et al. DERMATOLOGY
- Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006
- (2008) Jo-David Fine et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search